NEW YORK, June 3, 2019 /PRNewswire/ -- Neurotrope, Inc.
(Nasdaq: NTRP), a clinical-stage biopharmaceutical company
developing novel therapies for neurodegenerative diseases,
including Alzheimer's disease (AD), announced that Dr. Daniel L. Alkon, the Company's President and
CSO, will speak in Session II. From News Headlines to Patients:
Clinical Trial Ready Drugs (Part I).
Dr. Alkon's presentation - Bryostatin: A Natural Compound from
the Depths of the Ocean to Help Restore Neural Pathways and Reverse
Alzheimer's Memory Loss, will take place at the University of the Sciences at 600 S.
43rd St., Philadelphia,
PA on Monday, June
3rd, 2019, from 11:30am to
11:45am eastern time (Link- www.investacure.com).
Dr. Alkon stated: "Neurotrope therapeutics and clinical trials
are focusing on the causes and the consequences of
AD neurodegeneration. In a recently completed Phase 2
trial to treat advanced AD patients, Bryostatin, Neurotrope's lead
therapeutic, produced signals of positive improvement in
cognitive function for patients in the 20 µg Bryostatin-1 dose
group that were sustained - even 30 days after final treatment
dosing for some patients. The Severe Impairment Battery (SIB),
an accepted measure of cognition in advanced dementia
patients, was improved over placebo and baseline values for
patients in the 20 µg Bryostatin-1 dose group not on
memantine. Extensive pre-clinical studies suggest that
Bryostatin could potentially produce these benefits through
multiple efficacies: synaptogenesis, prevention of neuronal
death, anti-inflammation, anti- amyloid, and anti-neurofibrillary
tangles.
The dual efficacies of synaptogenesis via (synaptic growth
factors) and anti-apoptosis (prevention of neuronal death)
that address the degenerative AD consequences of lost brain
networks may be unique to the Bryostatin-activated PKC
epsilon pathway - that also addresses important contributing causes
of AD. Neurotrope expects to release results of a
confirmatory Phase 2 clinical trial using Bryostatin during the
second half of 2019."
About Neurotrope
Neurotrope is at the forefront of
developing a new approach to combating AD and other
neurodegenerative diseases. The Company's world-class science
offers the potential to realize a paradigm shift to overcome one of
today's most challenging clinical problems — finding a way to slow
or even prevent the progression of AD.
In addition to the Company's Phase 2 trial of Bryostatin-1 in
advanced AD, Neurotrope has also conducted preclinical studies of
Bryostatin-1 as a potential treatment for rare diseases and brain
injury, including Fragile X syndrome, multiple sclerosis, stroke,
Niemann-Pick Type C disease, Rett syndrome, and traumatic brain
injury. The U.S. Food and Drug Administration has granted Orphan
Drug Designation to Neurotrope for Bryostatin-1 as a treatment for
Fragile X. Bryostatin-1 has already undergone testing in more than
1,500 people in cancer studies, thus creating a large safety data
base that will further inform clinical trial designs.
Please visit www.neurotrope.com for further
information.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the Phase 2 study and further studies, and continued
development of use of Bryostatin-1 for AD and other cognitive
diseases. Such forward-looking statements are subject to risks and
uncertainties and other influences, many of which the Company has
no control over. There can be no assurance that the clinical
program for Bryostatin-1 will be successful in demonstrating safety
and/or efficacy that we will not encounter problems or delays in
clinical development, or that Bryostatin-1 will ever receive
regulatory approval or be successfully commercialized. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Additional
factors that may influence or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing,
the significant length of time associated with drug development and
related insufficient cash flows and resulting illiquidity, the
Company's patent portfolio, the Company's inability to expand the
Company's business, significant government regulation of
pharmaceuticals and the healthcare industry, lack of product
diversification, availability of the Company's raw materials,
existing or increased competition, stock volatility and
illiquidity, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the Securities and Exchange Commission, including the
Company's Annual Report on Form 10-K for the year ended
December 31, 2018, and on Form 10-Q
for the quarter ended March 31, 2019.
The Company does not undertake to update these forward-looking
statements.
Contact information:
Public Relations
Susan Roberts
sr@roberts-communications.com
202-779-0929
Investors and Media
Tom Caden
Vice President
CORE IR
516-222-2560
tomc@coreir.com
www.coreir.com
View original
content:http://www.prnewswire.com/news-releases/neurotropes-president-and-chief-scientific-officer-to-present-at-the-alzheimers-solutions-conference-at-the-university-of-the-sciences-in-philadelphia-pa-on-june-3rd-2019-300860139.html
SOURCE Neurotrope, Inc.